Developmental Pharmacology and Therapeutics

 

Prophylactic Treatment of Premature Babies with Artificial Surfactant (ALEC)

Morley C.J.

Author affiliations

Department of Paediatrics, University of Cambridge, UK

Related Articles for ""

Dev Pharmacol Ther 1989;13:182–183

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Published online: August 11, 2017
Issue release date: 1989

Number of Print Pages: 2
Number of Figures: 0
Number of Tables: 0

ISSN: 0379-8305 (Print)
eISSN: 2504-2505 (Online)

For additional information: https://www.karger.com/DPD

Abstract

Artificial surfactant (ALEC) made from DPPC and uPG 7:3 w/w has been given at birth to babies under 30 weeks of gestation in three trials. The first trial enrolled 62 resuscitated babies: 28 treated with 25 mg ALEC powder and 34 controls. The mortality fell from 41 to 7% (p = 0.0005). In the second trial babies were randomized to receive 1 ml of 100 mg ALEC suspension into the pharynx at birth and up to 3 more endotracheal doses in 24 h. Controls received 1 ml of saline. There were 69 ALEC-treated babies and 67 controls. The mortality due to complications of respiratory distress syndrome (RDS) fell from 31 to 9% (p < 0.01); periventricular haemorrhage was reduced from 40 to 19% ( p < 0.01). The third trial involved 328 babies randomized in 10 centres. ALEC treatment reduced the neonatal mortality from 27 to 14% (p < 0.002); intracerebral haemorrhages fell from 24 to 16% (p = 0.06) and severe RDS by 27% (p < 0.03). Regression analysis showed a significant reduction in hours receiving ventilation and > 30% oxygen during the first 10 days.




Related Articles:


Article / Publication Details

Published online: August 11, 2017
Issue release date: 1989

Number of Print Pages: 2
Number of Figures: 0
Number of Tables: 0

ISSN: 0379-8305 (Print)
eISSN: 2504-2505 (Online)

For additional information: https://www.karger.com/DPD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP